environmental risk-management in manufacturing and appropriate stewardship, highlighting the importance of site audits and setting discharge limits, as well as education on appropriate antibiotic use.
Our engagement revealed that companies are well-informed about the risks of antibiotic overuse. It is now unusual for European food and pharmaceutical companies not to have an antibiotic policy. However, very few food producers have committed to phasing out the use of antibiotics that are important to human medicine, and transparency varies.
In 2020, we will build on our dialogue with companies, broadening the scope of our project to include animal health companies, and will continue to benchmark best practices and encourage more robust commitments on addressing AMR.
You can learn more about our engagement on AMR in our ESG Viewpoint.